Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell TransplantationJonathan U. Peled, João B. Xavier, Niloufer Khan et al.|New England Journal of Medicine|2020Cited by 739
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Sham Mailankody, Andrea Knežević et al.|Blood Advances|2020Cited by 264
Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up GuidelinesEmanuela Romano, Paul B. Chapman, Michael Scordo et al.|Journal of Clinical Oncology|2010Cited by 253
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Malin Hultcrantz et al.|JAMA Oncology|2021Cited by 119
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical TrialSham Mailankody, Eric L. Smith, Arnab Ghosh et al.|Blood|2018Cited by 100